Approved studies using CPRD Data

Applications to access CPRD data for observational research are reviewed by the Independent Scientific Advisory Committee (ISAC). Approval by ISAC is required for researchers to carry out their proposed studies.

A summary of all ISAC-approved protocols, including a lay and technical summary of the proposed research, is published three months after researchers have access to the data to begin their study.

The table below includes all ISAC-approved protocols submitted to CPRD from 1st July 2015. Searches can be carried out using applicant names, approval date or by using key words within the protocol title. Protocols below are listed in order of date of approval.

 

ISAC Approval Date Title
19/11/2018 Reproducible Evidence: Practices to Enhance and Achieve Transparency (REPEAT): Study 18-Replication of "Risk of Myocardial infarction in Patients with Atrial Fibrillation using vitamin K antagonists, aspirin or direct acting oral anticoagulants"
19/11/2018 DPP-4 inhibitor dose selection according to Summaries of Product Characteristics: A contemporary experience from the UK General Practice
16/11/2018 An external validation of the SMART vascular event risk prediction model in a secondary prevention UK routine care cohort
14/11/2018 Reproducible Evidence: Practices to Enhance and Achieve Transparency (REPEAT) Study 19: Replication of "Long-term use of dipeptidyl peptidase-4 inhibitors and risk of fracture: A retrospective population-based cohort study."
13/11/2018 Proton pump inhibitor use and the risk of myocardial infarction: a nested case-control study in the UK Clinical Practice Research Datalink.
06/11/2018 Impact of recurrent hospitalization events on mortality in patients with Heart Failure: a retrospective analysis of a UK database
06/11/2018 A retrospective examination of glaucoma patients in the CPRD database with contraindications for anti-glaucoma beta-blocker therapy
06/11/2018 An analysis of linked healthcare datasets to examine the relationship between secondary prevention and long-term outcomes in patients with aortic disease in England
06/11/2018 Living with Ulcerative Colitis Study in England: A non-interventional, retrospective study in England to evaluate healthcare resource utilization and the direct healthcare cost of post-operative care in patients with ulcerative colitis
06/11/2018 Reproducible Evidence: Practices to Enhance and Achieve Transparency (REPEAT): Study 16 - "Use of tamoxifen and aromatase inhibitors in a large population-based cohort of women with breast cancer"
05/11/2018 Maternal and perinatal characteristics associated with Respiratory Tract Infection (RTI) healthcare utilisation and death in a birth cohort using the CPRD database and other linked databases
05/11/2018 Evaluation of probable treatment indications for the prescription of oral glycopyrronium in the United Kingdom - both licensed and off-label
31/10/2018 Determine the association between RSV/bronchiolitis episodes in young children and subsequent childhood episodes of wheeze and asthma (up to age 10 years), using a birth cohort
31/10/2018 Patient and practice level factors associated with influenza vaccine uptake among adults in England: a 7-year multi-level retrospective cohort study
30/10/2018 Reproducible Evidence: Practices to Enhance and Achieve Transparency (REPEAT):Study 15 - Replication of "Concurrent use of long-acting bronchodilators in COPD and the risk of adverse cardiovascular events."
29/10/2018 Burden of meningococcal disease (MD) in the UK during the period 2008-2017 - retrospective database analysis
25/10/2018 Antibiotic use and the risk of rheumatoid arthritis: a population-based case-control study
25/10/2018 Development and validation of a prognostic model for use in primary care which estimates the probability of individuals with non-diabetic hyperglycaemia developing type 2 diabetes
25/10/2018 Burden of Hypereosinophilic syndrome (HES) in the UK
12/10/2018 Reproducible Evidence: Practices to Enhance and Achieve Transparency (REPEAT): Study 13 - Replication of "Metformin and the incidence of viral associated cancers in patients with type 2 diabetes."